Interferon Gamma 1 b Articles
Former Biotech CEO Harkonen convicted of wire fraud
5 October 2009
InterMune/Boeh Ing agree Actimmune supply accord
26 July 2007
InterMune's 1st-qtr loss increases to $20.8M
21 May 2007
InterMune cuts costs: workforce slashed 50%
2 April 2007
InterMune stops Ph III Actimune IPF study
12 March 2007
InterMune completes enrollment in Ph III Actimmune trial
24 April 2006
InterMune posts 2004 results
21 February 2005
InterMune posts 2004 results
21 February 2005
InterMune subpoenaed in USA
15 November 2004
InterMune cuts 3rd-qtr 2004 loss 63%
8 November 2004
InterMune's net loss falls 36% for 2nd-qtr
9 August 2004
InterMune losses tumble 38%
10 May 2004
InterMune's Actimmune fails in trial
2 February 2004
InterMune forecasts
23 June 2003
InterMune dips on follow-up study data
13 January 2003
InterMune acquires Amgen patent estate
20 May 2002
InterMune starts Ph III ovarian cancer trial
11 February 2002
InterMune starts trial of Actimmune in liver fibrosis
14 January 2002
InterMune switches Actimmune production
20 September 2001
InterMune completes Ph III IPF trial enrollment
23 August 2001
InterMune forecasts larger losses
18 June 2001
InterMune share sale may raise $120 million
7 June 2001
Boehringer Ingelheim and Intermune link up on IFN gamma
29 March 2001
Actimmune tested in cystic fibrosis
1 March 2001
InterMune expands US sales team
1 February 2001
InterMune buys Alza's Amphotec with upfront payment of $9 mill
11 January 2001
FDA OK's InterMune's osteopetrosis therapy
15 February 2000
InterMune IPO could raise $88 million
4 February 2000
$27 million financing for InterMune
11 January 2000
InterMune to test IFN gamma in IPF
5 November 1999
InterMune files BLA for Actimmune
26 August 1999
Connetics Abandons Gamma Interferon
4 September 1997
Connetics' Pipeline A Credit To 4-Year-Old Firm
23 July 1997
Genentech Drops Actimmune For Renal Cell Carcinoma
17 June 1996
IDEC/Genentech's Anti-CD20 Antibody In Phase III Soon?
27 March 1995
Genentech Presentation Pleases Analysts
17 October 1994
BIOPHARMACEUTICALS MARKET GROWING FAST
13 June 1994
PROFITS MORE THAN DOUBLE AT GENENTECH
25 April 1994
PMA WARNING ON FUTURE OF BIOTECHNOLOGY
27 September 1993
PROFITS SOAR FOR GENENTECH IN 2ND QTR
19 July 1993
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
REVENUES RISE AT GENENTECH
25 January 1993
GENENTECH'S EXPANDING PRODUCT PORTFOLIO
11 May 1992
IMPROVEMENTS IN 1ST QTR FOR US FIRMS
20 April 1992
EFPIA CHALLENGES EC DRAFT ON DRUG PRICING
16 March 1992
Showing 1-49 of 49 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
